3-iodobenzylguanidine has been researched along with topotecan in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YC; Flux, GD; Gaze, MN; Mairs, RJ; Meller, ST; Saran, FH | 1 |
| Boyd, M; Gaze, MN; Mairs, RJ; McCluskey, AG | 1 |
| Angerson, WJ; Boyd, M; Clark, AM; Cosimo, E; Gaze, MN; Mairs, RJ; McCluskey, AG; Ross, SC | 1 |
| Martin, S | 1 |
| Boyd, M; Mairs, RJ | 1 |
| Babich, JW; Boyd, M; Gaze, MN; Mairs, RJ; McCluskey, AG; Pimlott, SL | 1 |
| Babich, JW; Boyd, M; Champion, S; Gaze, MN; Mairs, RJ; McCluskey, AG; Pimlott, SL; Tesson, M | 1 |
| Caron, HN; Kam, B; Kraal, KC; Tytgat, GA; van Eck-Smit, BL; van Noesel, M | 1 |
| Carpentier, P; Clisant, S; Cougnenc, O; Defachelles, AS; Kolesnikov-Gauthier, H; Lervat, C; Oudoux, A | 1 |
| Kraal, KC; Tytgat, GA; van Dalen, EC; Van Eck-Smit, BL | 1 |
| Bogart, E; Chastagner, P; Cougnenc, O; Defachelles, AS; Ferry, I; Kolesnikov-Gauthier, H; Michon, J; Oudoux, A; Proust, S; Schleiermacher, G; Valteau-Couanet, D | 1 |
| Echebarria, A; Genolla, J; Llorens, V; Lopez-Almaraz, R; Minguez, P; Rodriguez, T | 1 |
| Badel, JN; Bogart, E; Corradini, N; Cougnenc, O; Courbon, F; Defachelles, AS; Deley, MCL; Gambart, M; Giraudet, AL; Kolesnikov-Gauthier, H; Oudoux, A; Rault, E; Schleiermacher, G; Sevrin, F; Valteau-Couanet, D | 1 |
3 review(s) available for 3-iodobenzylguanidine and topotecan
| Article | Year |
|---|---|
[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Combined Modality Therapy; DNA Damage; Enzyme Inhibitors; Humans; Neuroblastoma; Radiopharmaceuticals; Topoisomerase I Inhibitors; Topotecan | 2005 |
Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Topics: 3-Iodobenzylguanidine; Bystander Effect; Combined Modality Therapy; Humans; Neuroendocrine Tumors; Radiopharmaceuticals; Radiotherapy Dosage; Topotecan | 2008 |
Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neuroblastoma; Observational Studies as Topic; Radiopharmaceuticals; Thyroid Diseases; Topotecan | 2017 |
4 trial(s) available for 3-iodobenzylguanidine and topotecan
| Article | Year |
|---|---|
Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Infant; Infant, Newborn; Male; Neuroblastoma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Topotecan; Transplantation Conditioning | 2015 |
HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Topics: 3-Iodobenzylguanidine; Adult; Caregivers; Child; Female; France; Humans; Iodine Radioisotopes; Male; Neoplasm Recurrence, Local; Neuroblastoma; Radiation Exposure; Radiometry; Topoisomerase I Inhibitors; Topotecan | 2017 |
Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Metastasis; Neuroblastoma; Risk Factors; Topotecan | 2018 |
Phase II study of
Topics: 3-Iodobenzylguanidine; Adolescent; Busulfan; Child; Child, Preschool; Chronic Disease; Humans; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Young Adult | 2023 |
6 other study(ies) available for 3-iodobenzylguanidine and topotecan
| Article | Year |
|---|---|
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Topics: 3-Iodobenzylguanidine; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; Humans; Iodine Radioisotopes; Male; Neoplasm Metastasis; Neuroblastoma; Radiation Dosage; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Topotecan; Whole-Body Counting | 2005 |
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Comet Assay; DNA Damage; DNA Fragmentation; DNA, Complementary; Glioma; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Time Factors; Topotecan; Transfection | 2005 |
New Agents in Clinical Oncology. 24 November 2006, London, UK.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Combined Modality Therapy; Enzyme Inhibitors; Humans; Medical Oncology; Neoplasms; Norepinephrine Plasma Membrane Transport Proteins; Poly(ADP-ribose) Polymerase Inhibitors; Proteomics; Stilbenes; Thioredoxins; Topotecan | 2007 |
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; Glioma; Mice; Mice, Nude; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Radiopharmaceuticals; Topotecan; Treatment Outcome | 2008 |
Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Combined Modality Therapy; DNA Breaks; Female; Flow Cytometry; Histones; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiopharmaceuticals; Topotecan; Tumor Stem Cell Assay | 2012 |
Dosimetry-based high-activity therapy with
Topics: 3-Iodobenzylguanidine; Adolescent; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Progression-Free Survival; Radiometry; Recurrence; Remission Induction; Retrospective Studies; Risk; Topotecan; Treatment Outcome; Young Adult | 2019 |